The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC)
investigates tumors from a proteogenomic perspective, creating rich multi-omics datasets …

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …

Background Ductal carcinoma in situ (DCIS) is the most common type of in situ premalignant
breast cancers. What drives DCIS to invasive breast cancer is unclear. Basal-like invasive …

We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and
neck squamous cell carcinomas (HNSCCs). Proteomic analysis systematically catalogs …

We undertook a comprehensive proteogenomic characterization of 95 prospectively collected
endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis …

Clear cell renal cell carcinomas (ccRCCs) represent ∼75% of RCC cases and account for
most RCC-associated deaths. Inter- and intratumoral heterogeneity (ITH) results in varying …

The integration of mass spectrometry-based proteomics with next-generation DNA and RNA
sequencing profiles tumors more comprehensively. Here this "proteogenomics" approach …

In current time the environment is heavily polluted by various toxic metals, which create a
danger for all living beings. These metals are retarding farming efficiency and destructing the …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-…

Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of
chemotherapy response associations, including a 19q13.31–33 somatic deletion encoding …